chromium polynicotinate

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• antiretroviral-induced insulin resistance [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• binge eating disorder [Insufficient Evidence]
• bipolar disorder [Insufficient Evidence]
• chromium deficiency [Likely Effective]
• cognitive impairment, mild [Insufficient Evidence]
• depression [Insufficient Evidence]
• diabetes mellitus [Possibly Effective]
• dyslipidemia, beta blocker-related [Insufficient Evidence]
• HTN [Possibly Ineffective]
• hypoglycemia [Insufficient Evidence]
• hyperlipidemia [Insufficient Evidence]
• impaired glucose tolerance [Possibly Ineffective]
• metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
• metabolic syndrome [Insufficient Evidence]
• MI prevention [Insufficient Evidence]
• obesity [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• schizophrenia [Possibly Ineffective]
• Turner syndrome [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

antiretroviral-induced insulin resistance

[Insufficient Evidence]

Dose: 200 mcg chromium nicotinate PO qd; Alt: 1000 mcg chromium picolinate PO qd

athletic performance

[Insufficient Evidence]

Dose: 400 mcg chromium picolinate PO qd

bipolar disorder

[Insufficient Evidence]

Dose: 600-800 mcg chromium chloride PO qd

chromium deficiency, adult patients

[Likely Effective]

Dose: 25 mcg PO qd in female patients 19-50 yo; 20 mcg PO qd in female patients 51 yo and older; 35 mcg PO qd in male patients 19-50 yo; 30 mcg PO qd in male patients 51 yo and older; Info: based on established daily adequate intake levels

chromium deficiency, peds patients

[Likely Effective]

Dose: 0.2 mcg PO qd in patients 0-6 mo; 5.5 mcg PO qd in patients 7-12 mo; 11 mcg PO qd in patients 1-3 yo; 15 mcg PO qd in patients 4-8 yo; 21 mcg PO qd in female patients 9-13 yo; 24 mcg PO qd in female patients 14-18 yo; 25 mcg PO qd in male patients 9-13 yo; 35 mcg PO qd in male patients 14-18 yo; Info: based on established daily adequate intake levels

cognitive impairment, mild

[Insufficient Evidence]

Dose: 1000 mcg chromium picolinate PO qd

depression

[Insufficient Evidence]

Dose: 600 mcg chromium picolinate PO qd; Start: 400 mcg PO qd x2wk

diabetes mellitus

[Possibly Effective]

Dose: 42-1000 mcg/day PO divided qd-tid; Alt: 4-8 mcg/kg/day chromium picolinate PO qd

dyslipidemia, beta blocker-related

[Insufficient Evidence]

Dose: 200 mcg PO tid

hyperlipidemia, adult patients

[Insufficient Evidence]

Dose: 42-1000 mcg PO qd; Alt: 200 mcg chromium polynicotinate PO bid; 200 mcg chromium picolinate PO qd; 250 mcg chromium chloride PO qd

hyperlipidemia, peds patients

[Insufficient Evidence]

Dose: 400-600 mcg chromium polynicotinate PO bid

hypoglycemia

[Insufficient Evidence]

Dose: 200 mcg chromium chloride PO qd; Alt: 125 mcg chromium yeast PO qd

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 200-1000 mcg/day chromium picolinate PO divided qd-tid

rheumatoid arthritis

[Insufficient Evidence]

Dose: approximately 3.5 mcg/kg/day PO qd; Info: given before meals

Turner syndrome

[Insufficient Evidence]

Dose: 50 mcg PO qd